Inmune Bio (INMB)
NASDAQ:INMB
Want to see INMB full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.19Last Year’s EPS
-1.05Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 07, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.Company Guidance
CORDStrom regulatory progress (PIP and MAA preparation)
Submitted Pediatric Investigation Plan (PIP) to U.K. regulator; approved for rapid assessment with response received April 9 and no substantial issues raised. Marketing Authorization Application (MAA) documentation across five sections is well underway; company expects to submit to MHRA in early Q3 and is targeting parallel EMA/FDA filings to meet the previously stated end-of-year filing timeline.
Manufacturing readiness and supply secured
Started the first of three process validation manufacturing runs on time, with two remaining runs scheduled to meet MAA deadlines. Concluded and signed an amended material transfer agreement with the Anthony Nolan U.K. Cord Blood Bank to secure long-term, high-quality umbilical cord tissue supply and permit U.S. lab testing required by the FDA (per prior Type B meeting).
Product definitions and commercialization planning
Active ingredient named by WHO as pobistrocel and company selected commercial drug name Ebstracel for the RDEB formulation; preparing regulatory and commercial documentation and engaging TMC Pharma (rare disease submission expertise) to run EMA and FDA submissions in parallel.
Progress on XPro clinical characterization
Advancing additional imaging analyses from the MINDFuL study, including MRI data focused on myelin preservation and structural integrity to further characterize XPro's potential as a disease-modifying therapy; exploring rare disease trial opportunities and partnership discussions for late-stage development.
Reduced quarterly net loss
Net loss attributable to common stockholders for Q1 2026 was $5.4 million versus $9.7 million in Q1 2025, a reduction of approximately 44.3% year-over-year, reflecting lower operating spend this quarter.
Lower R&D and stable G&A expenses; cash runway disclosed
R&D expenses decreased to $3.6 million in Q1 2026 from $7.6 million in Q1 2025 (approximately a 52.6% reduction). General and administrative expenses were roughly flat at $2.2 million versus $2.3 million (about a 4.3% decrease). Cash and cash equivalents were $21.4 million as of March 31, 2026, and management believes cash is sufficient to fund operations through Q1 2027; shares outstanding were ~26.6 million as of May 7, 2026.
INMB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INMB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $1.43 | $1.43 | 0.00% |
Mar 30, 2026 | $1.14 | $1.13 | -0.88% |
Oct 30, 2025 | $1.73 | $1.83 | +5.78% |
Aug 07, 2025 | $2.79 | $2.56 | -8.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inmune Bio (INMB) report earnings?
Inmune Bio (INMB) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Inmune Bio (INMB) earnings time?
Inmune Bio (INMB) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INMB EPS forecast?
INMB EPS forecast for the fiscal quarter 2026 (Q2) is -0.19.